Medtronic Plc  (MDT)
Other Ticker:  
Price: $104.2600 $1.73 1.687%
Day's High: $104.44 Week Perf: -1.88 %
Day's Low: $ 103.41 30 Day Perf: -3.28 %
Volume (M): 176 52 Wk High: $ 135.89
Volume (M$): $ 18,238 52 Wk Avg: $116.45
Open: $103.53 52 Wk Low: $98.38

 Market Capitalization (Millions $) 140,782
 Shares Outstanding (Millions) 1,350
 Employees 90,000
 Revenues (TTM) (Millions $) 31,785
 Net Income (TTM) (Millions $) 4,935
 Cash Flow (TTM) (Millions $) -1,598
 Capital Exp. (TTM) (Millions $) 1,356

Medtronic Plc
Medtronic is a world leading medical technology company, providing lifelong solutions for people with chronic disease. We are committed to offering market-leading therapies worldwide to restore patients to fuller, healthier lives. With beginnings in the treatment of heart disease, we have expanded well beyond our historical core business and today provide a wide range of products and therapies that help solve many challenging, life-limiting medical conditions. We hold market-leading positions in almost all of the major markets in which we compete.

We currently function in five operating segments that manufacture and sell device-based medical therapies. Our operating segments are:

• Cardiac Rhythm Management (CRM)

• Spinal, Ear, Nose and Throat (ENT) and Surgical Navigation Technologies (SNT)

• Neurological and Diabetes

• Vascular

• Cardiac Surgery

Medtronic was founded in 1949, incorporated as a Minnesota corporation in 1957 and today serves physicians, clinicians and patients in more than 120 countries worldwide. Beginning with the development of the heart pacemaker in the 1950s, we have assembled a broad and diverse portfolio of progressive technology expertise both through internal development of core technologies as well as acquisitions. We remain committed to a mission written by our founder more than 40 years ago that directs us "to contribute to human welfare by application of biomedical engineering in the research, design, manufacture and sale of products that alleviate pain, restore health and extend life."

our success in leading global advances in medical technology is rooted in several key strengths:

• Broad and deep technological knowledge of microelectronics, implantable devices and techniques, power sources, coatings, materials, programmable devices and related areas, as well as a tradition of technological pioneering and breakthrough products that not only yield better medical outcomes, but more cost-effective therapies.

• Strong intellectual property portfolio that underlies our key products.

• High product quality standards, backed with stringent systems to ensure consistent performance, that meet or surpass customers' expectations.

• Strong professional collaboration with customers, extensive medical educational programs and thorough clinical research.

• Full commitment to superior patient and customer service.

• Long experience with the regulatory process and sound working relationships with regulators and reimbursement agencies, including leadership roles in helping shape policy.

• A proven financial record of sustained growth and continual introduction of new products.

Customers and Competitors

The primary medical specialists who use our implanted cardiac rhythm devices include electrophysiologists, implanting cardiologists and cardiovascular surgeons. We hold the leading market position among implantable cardiac rhythm device manufacturers. Our primary competitors in this business are Guidant Corporation and St. Jude Medical, Inc.

The primary medical specialists who use our spinal and SNT products are spine surgeons, orthopedic surgeons and neurosurgeons. The primary medical specialists who use our ENT products are ENT surgeons (otorhinolaryngologists). Our primary competitors in the Spinal business are Zimmer Inc., Johnson & Johnson, Inc., Stryker Corporation, and Synthes-Stratec, Inc.; the most significant competitors in the ENT business are Gyrus Group PLC and Stryker Corporation; and the primary competitors in the SNT business are BrainLAB, Inc. and Stryker Corporation.

The primary medical specialists who use our neurological products are neurosurgeons, neurologists, pain management specialists, and orthopedic spine surgeons. The primary medical specialists who use our diabetes products are endocrinologists and internists, and those who use our gastroenterology and urology products are urologists, urogynecologists and gastroenterologists. Our primary competitors for neurological products are Advanced Neuromodulation Systems, Inc., Johnson  & Johnson, Inc., Boston Scientific Corporation and Stryker Corporation. Our most significant competitors for diabetes products are Animas Corporation, Roche Ltd. and Smiths Group plc. Our primary competitors for gastroenterology and urology products are Boston Scientific Corporation and Urologix, Inc.

The primary medical specialists who use our products for treating coronary artery disease are interventional cardiologists, while products treating peripheral vascular disease may be used by interventional radiologists, vascular surgeons and interventional cardiologists. Our primary competitors in the Vascular business are Boston Scientific Corporation, Guidant Corporation and Johnson & Johnson,  Inc.

The principal medical specialists who use our cardiac surgery products are cardiac surgeons. Our primary competitors in the Cardiac Surgery business are Edwards LifeSciences Corporation, Guidant Corporation, Johnson & Johnson, Inc., and St. Jude Medical, Inc.

   Company Address: 20 On Hatch, Lower Hatch Street Dublin 2 0
   Company Phone Number: 438-1700   Stock Exchange / Ticker: NYSE MDT
   MDT is expected to report next financial results on September 01, 2022.

Customers Net Income fell by MDT's Customers Net Profit Margin fell to

-5.78 %

3.5 %

• Customers Performance • Customers Expend. • Customers Efficiency • List of Customers


Stock Performances by Major Competitors

Year to Date Decrease / Increase
BDX        1.5% 
BSX   -7.49%    
EW   -26.51%    
ISRG   -38.44%    
PDCO        7.23% 
SYK   -13.18%    
ABT   -17.27%    
DHR   -19.84%    
GE   -21.59%    
JNJ        4.61% 
• View Complete Report

Newhydrogen Inc.

Newhydrogen Inc reported first quarter of 2021 operating deficit of $-2.801696 millions

In the first quarter of 2021 Newhydrogen Inc reached break-even of $0.00 per share compared to $0.05 a year ago and from $-0.02 per share from the previous quarter.

American International Holdings Corp.

Despite Strong Sales Profitability not Reached at American International Holdings Corp in the fiscal first quarter of 2022

Although company's Sales increased by 10.68% from the same quarter a year ago to $0.01 millions in the fiscal first quarter of 2022, American International Holdings Corp increased losses at $-0.90 loss per share.

Ast Spacemobile Inc.

Losses Widen by Ast Spacemobile Inc in the fiscal interval ending Mar 31 2022 release

In the fiscal interval ending Mar 31 2022 Ast Spacemobile Inc increased losses of $-0.21 per share compared to $0.00 a year ago and eps fell from $0.32 per share from the previous quarter.

Pillarstone Capital Reit

Pillarstone Capital Reit disclosed that Sales went up modestly in the first quarter of 2022 earnings season

In the first quarter of 2022 earnings season Pillarstone Capital Reit decreased loss of $-0.03 per share compared to $-0.12 a year ago and improved from $-0.11 per share from the previous quarter.

Security Federal Corporation

Weak Demand Cause for EPS Slide at Security Federal Corporation in the fiscal interval ending Mar 31 2022

In the fiscal interval ending Mar 31 2022 earnings per share plummeted by -51.02 % to $0.48 per share due to Revenue decrease of -9.9% to $10.51 millions, year on year.


Medtronic Plc's Segments
Cardiac Rhythm Management
 Segment    30.23 % of total Revenue
 Segment    9.85 % of total Revenue
Spinal & ENT
 Segment    17.09 % of total Revenue
 Segment    17.02 % of total Revenue
 Segment    11.31 % of total Revenue
 Segment    9.39 % of total Revenue
Cardiac Vascular
 Segment    52.36 % of total Revenue
Restorative Therapies
 Segment    37.79 % of total Revenue
• View Complete Report
  Company Estimates  
  Revenue Outlook
Medtronic Plc does not provide revenue guidance.

Earnings Outlook
Security Federal Corporation does not provide earnings estimates.

Geographic Revenue Dispersion
United States 54.15 %
Europe 25.76 %
Asia Pacific 15.29 %
Other 4.8 %


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production


Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales


Event Calendar

UUUU's Profile

Stock Price

UUUU's Financials

Business Description


Charts & Quotes

UUUU's News


UUUU's Competitors

Customers & Markets

Economic Indicators

UUUU's Growth

Company Segments


Stock Performance

Growth Rates




Financial Strength


Largest Companies

Management Effectivness


At a Glance


Growth Rates



Financial Strength


At a Glance



Sectors & Industries






About us


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.    Copyright © 2022 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071